Medication-related Problems in CKD

      Patients with CKD are often prescribed heterogeneous medications to treat disease-associated comorbidities, to slow down progression of the disease, and to minimize morbidity and mortality rates. However, the medication regimens of this population are very complex, leading to an increased potential for medication-related problems (MRPs). As kidney function declines, the type and amount of medications a patient consumes increases, thereby putting them at a higher risk for MRPs. MRPs have been known to be associated with morbidity, mortality, and a lower quality of life. This review will summarize data on the prevalence and effect of MRPs, and strategies that can be used by clinicians to reduce and resolve MRPs.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Coresh J.
        • Selvin E.
        • Stevens L.A.
        • et al.
        Prevalence of chronic kidney disease in the United States.
        JAMA. 2007; 298: 2038-2047
      1. United States Renal Data Systems (USRDS): 2009 Annual Data Report.
        National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD2009
        • Patel H.R.
        • Pruchnicki M.C.
        • Hall L.E.
        Assessment for chronic kidney disease service in high-risk patients at community health clinics.
        Ann Pharmacother. 2005; 39: 22-27
        • Manley H.J.
        • Garvin C.G.
        • Drayer D.K.
        • et al.
        Medication prescribing patterns in ambulatory hemodialysis patients: Comparisons of USRDS to a large non-for-profit dialysis provider.
        Nephrol Dial Transplant. 2004; 19: 1842-1848
        • Ernst F.R.
        • Grizzle A.J.
        Drug-related morbidity and mortality: Updating the cost-of-illness model.
        J Am Pharm Assoc. 2001; 41: 192-199
        • Hepler C.D.
        • Strand L.M.
        Opportunities and responsibilities in pharmaceutical care.
        Am J Hosp Pharm. 1990; 47: 533-543
        • Manley H.J.
        • McClaran M.L.
        • Overbay D.K.
        • et al.
        Factors associated with medication-related problems in ambulatory hemodialysis patients.
        Am J Kidney Dis. 2003; 41: 386-393
        • Winterstein A.G.
        • Sauer B.C.
        • Hepler C.D.
        • et al.
        Preventable drug-related hospital admissions.
        Ann Pharmacother. 2002; 36: 1238-1248
        • Koecheler J.A.
        • Abramowitz P.W.
        • Swim S.E.
        • et al.
        Indicators for the selection of ambulatory patients who warrant pharmacist monitoring.
        Am J Hosp Pharm. 1989; 46: 729-732
        • Manley H.J.
        • Cannella C.A.
        Nondialysis (home) medication utilization and cost in diabetic and nondiabetic hemodialysis patients.
        Nephrol News Issues. 2005; 19 (27-28, 33-34, 36–38)
      2. United States Renal Data Systems (USRDS): 2000 Annual Data Report.
        National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD2000
        • Bleyer A.J.
        • Hylander B.
        • Sudo H.
        • et al.
        An international study of patient compliance with hemodialysis.
        JAMA. 1999; 281: 1211-1213
        • Long J.M.
        • Kee C.C.
        • Graham M.W.
        • et al.
        Medication compliance and the older hemodialysis patient.
        ANNA J. 1998; 25: 43-49
        • Curtin R.B.
        • Svarstad B.L.
        • Keller T.H.
        Hemodialysis patients’ noncompliance with oral medications.
        ANNA J. 1999; 26: 307-316
        • Bander S.J.
        • Walters B.A.
        Hemodialysis morbidity and mortality: Links to patient non-compliance.
        Curr Opin Nephrol Hypertens. 1998; 7: 649-653
        • Leggat J.E.
        • Orzol S.M.
        • Hulbert-Shearon T.E.
        • et al.
        Noncompliance in hemodialysis: Predictors and survival analysis.
        Am J Kidney Dis. 1998; 32: 139-145
        • Denhaerynck K.
        • Manhaeve D.
        • Dobbels F.
        • et al.
        Prevalence and consequences of nonadherence to hemodialysis regimens.
        Am J Crit Care. 2007; 16: 222-235
        • Manley H.J.
        • Drayer D.K.
        • McClaran M.
        • et al.
        Drug record discrepancies in an outpatient electronic medical record: Frequency, type, and potential impact on patient care at a hemodialysis center.
        Pharmacotherapy. 2003; 23: 231-239
        • Pai A.B.
        • Boyd A.
        • Depczynski J.
        • et al.
        Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: A 2-year, randomized, controlled study.
        Pharmacotherapy. 2009; 29: 1433-1440
        • Hug B.L.
        • Witkowski D.J.
        • Sox C.M.
        • et al.
        Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney.
        Kidney Int. 2009; 76: 1192-1198
        • Pai A.B.
        • Boyd A.
        • Chavez A.
        • et al.
        Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: A 2-year randomized, controlled study.
        Hemodial Int. 2009; 13: 72-79
        • Ong S.W.
        • Fernandes O.A.
        • Cesta A.
        • et al.
        Drug-related problems on hospital admission: Relationship to medication information transfer.
        Ann Pharmacother. 2006; 40: 408-413
        • Manley H.J.
        • Cannella C.L.
        • Bailie G.R.
        • et al.
        Medication-related problems in ambulatory hemodialysis patients: A pooled analysis of published reports.
        Am J Kidney Dis. 2005; 46: 669-680
        • Manley H.J.
        • Drayer D.K.
        • Muther R.S.
        Medication-related problem type and appearance rate in ambulatory hemodialysis patients.
        BMC Nephrol. 2003; 4: 10
        • Possidente C.J.
        • Bailie G.R.
        • Hood V.L.
        Disruptions in drug therapy in long-term dialysis patients who require hospitalization.
        Am J Health Syst Pharm. 1999; 56: 1961-1964
        • Grabe D.W.
        • Low C.L.
        • Bailie G.R.
        • et al.
        Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist.
        Clin Nephrol. 1997; 121: 459-464
        • Kaplan B.
        • Shimp L.A.
        • Mason N.A.
        • et al.
        Chronic hemodialysis patients. Part II: Reducing drug-related problems through application of the focused drug therapy review program.
        Ann Pharm. 1994; 28: 320-324
        • Kaplan B.
        • Mason N.A.
        • Shimp L.A.
        • et al.
        Chronic hemodialysis patients. Part I: Characterization and drug-related problems.
        Ann Pharm. 1994; 28: 316-318
        • Tang I.
        • Vrahnos D.
        • Hatoum H.
        • et al.
        Effectiveness of clinical pharmacist interventions in a hemodialysis unit.
        Clin Therapeut. 1993; 15: 459-464
        • Bailie G.R.
        • Eisele G.
        • Liu L.
        • et al.
        Patterns of medication use in the RRI-CKD study: Focus on medications with cardiovascular effects.
        Nephrol Dial Transplant. 2005; 20: 1110-1115
        • Nissenson A.R.
        • Collins A.J.
        • Hurley J.
        • et al.
        Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns.
        J Am Soc Nephrol. 2001; 12: 1713-1720
        • Kausz A.T.
        • Khan S.S.
        • Abichandani R.
        • et al.
        Management of patients with chronic renal insufficiency in the Northeastern United States.
        J Am Soc Nephrol. 2001; 12: 1501-1507
        • Tozawa M.
        • Iseki K.
        • Iseki C.
        • et al.
        Analysis of drug prescription in chronic hemodialysis patients.
        Nephrol Dial Transplant. 2002; 17: 1819-1824
        • Manley H.J.
        • Carroll C.
        The clinical and economic impact of pharmaceutical care in end-stage renal disease patients.
        Semin Dial. 2002; 15: 45-49
        • Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group
        KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
        Kidney Int. 2009; 76: S113
        • Hirth R.A.
        • Greer S.L.
        • Albert J.M.
        • Young E.W.
        • Piette J.D.
        Out of pocket spending and medication adherence among dialysis patients in twelve countries.
        Health Affairs. 2008; 27: 89-103
        • Kripalani S.
        • Yao X.
        • Haynes R.B.
        Interventions to enhance medication adherence in chronic medical conditions: A systematic review.
        Arch Intern Med. 2007; 167: 540-550
        • Holley J.L.
        • Devore C.C.
        Why all prescribed medications are not taken: Results from a survey of chronic dialysis patients.
        Adv Perit Dial. 2006; 22: 162-166
      3. Patient Protection and Affordable Care Act. HR 4872–9, Section 1860D–42 of the Social Security Act (42 U.S.C. 1395w–152)

        • Doshi J.A.
        • Zhu J.
        • Lee B.Y.
        • et al.
        Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans.
        Circulation. 2009; 119: 390-397
        • Miller W.R.
        • Rollnick S.
        Motivational interviewing: Preparing people for change.
        2nd ed. Guilford Press, New York, NY2002
        • Miller W.R.
        • Rollnick S.
        What is MI?.
        Behav Cognit Psychother. 1995; 23: 325-334
        • Mason N.A.
        • Bakus J.
        Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease.
        Semin Dial. 2009; 23: 55-61
        • Wang H.Y.
        • Chan A.L.
        • Chen M.T.
        • et al.
        Effects of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics.
        Transplant Proc. 2008; 40: 2319-2323
        • Chisholm M.A.
        • Vollenweider L.J.
        • Mulloy L.L.
        • et al.
        Direct patient care services provided by a pharmacist on a multidisciplinary renal transplant team.
        Am J Health Syst Pharm. 2000; 57: 1994-1996
        • Harchowal J.T.
        Drug-related problems on a renal unit.
        Br J Renal Med. 1997; 2: 22-24
        • Manley H.J.
        • Drayer D.K.
        Identification and resolution of cardiovascular medication-related problems in hemodialysis (HD) patients: A 3 year experience.
        J Am Soc Nephrol. 2005; 16: 472A
        • Joy M.S.
        • Matzke G.R.
        Nephrology pharmacy: Historical reflections and future challenges.
        Ann Pharmacother. 2007; 41: 1884-1886